secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-09-12T23:59:59+00:00
Accession:  0001104659-25-089564
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma acquires antiviral compound assets from Viriom for $2.35M cash
---------------------------------------------------------------------------

- Acquired IP and assets for pyrrolidine antiviral compound from Viriom for $2,350,000 cash paid on September 9, 2025.
- Nikolay Savchuk, Traws COO, is Executive Chairman of Viriom; Dr. Robert Redfield, Traws CMO, on Viriom board; related-party transaction approved by audit committee.
- Assets include patents, license agreements, regulatory filings, and materials exclusively related to the compound and program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/0001104659-25-089564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925089564/tm2526017d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-089564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer